度鲁特韦-话题@MedSci

#度鲁特韦#

10篇内容 | 1379人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2275149, encodeId=2e6322e5149b1, content=<a href='/topic/show?id=d85d65066a9' target=_blank style='color:#2F92EE;'>#泰诺福韦#</a> <a href='/topic/show?id=754991e9f6' target=_blank style='color:#2F92EE;'>#HTLV-1#</a> <a href='/topic/show?id=904e11381c1' target=_blank style='color:#2F92EE;'>#Mcl-1#</a> <a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, objectTitle=Cell：新研究确定了世界上首个有望预防危及生命的HTLV-1病毒感染的新方法, objectType=article, longId=888711, objectId=7f84888e11fc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20250726/1753527652302_2185383.jpeg, objectUrl=/article/show_article.do?id=7f84888e11fc, replyNumber=0, likeNumber=5, createdTime=2025-07-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1649237, encodeId=56c1164923e6a, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, objectTitle=N Engl J Med：度鲁特韦（Dolutegravir）作为儿童HIV-1感染的一线或二线治疗优于标准治疗, objectType=article, longId=293179, objectId=48b22931e963, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48b22931e963, replyNumber=0, likeNumber=77, createdTime=2022-05-04, rootId=0, userName=zhyy96, userId=42c123781077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48b22931e963, moduleTitle=N Engl J Med：度鲁特韦（Dolutegravir）作为儿童HIV-1感染的一线或二线治疗优于标准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48b22931e963)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649236, encodeId=d59416492364e, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, objectTitle=NEJM：HIV感染二线治疗选择——度鲁特韦方案vs达芦那韦方案, objectType=article, longId=214784, objectId=2ebb214e8446, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ebb214e8446, replyNumber=0, likeNumber=85, createdTime=2021-11-20, rootId=0, userName=zhyy96, userId=42c123781077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ebb214e8446, moduleTitle=NEJM：HIV感染二线治疗选择——度鲁特韦方案vs达芦那韦方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ebb214e8446)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649235, encodeId=0bb91649235be, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, objectTitle=Lancet HIV：度鲁特韦作为一线ART方案效果模型研究, objectType=article, longId=187583, objectId=502f18e58307, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=502f18e58307, replyNumber=0, likeNumber=81, createdTime=2020-11-06, rootId=0, userName=zhyy96, userId=42c123781077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=502f18e58307, moduleTitle=Lancet HIV：度鲁特韦作为一线ART方案效果模型研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=502f18e58307)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649234, encodeId=7265164923430, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, objectTitle=NEJM：度鲁特韦联合富马酸替诺福韦治疗HIV, objectType=article, longId=178385, objectId=90d61e838552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90d61e838552, replyNumber=0, likeNumber=0, createdTime=2019-09-18, rootId=0, userName=zhyy96, userId=42c123781077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90d61e838552, moduleTitle=NEJM：度鲁特韦联合富马酸替诺福韦治疗HIV, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90d61e838552)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649232, encodeId=f6bb1649232a0, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, objectTitle=真实世界研究显示，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法是HIV-1患者安全且有效的疗法, objectType=article, longId=163954, objectId=7a891639548d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a891639548d, replyNumber=0, likeNumber=65, createdTime=2019-05-22, rootId=0, userName=zhyy96, userId=42c123781077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a891639548d, moduleTitle=真实世界研究显示，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法是HIV-1患者安全且有效的疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a891639548d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649233, encodeId=8f1816492335c, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, objectTitle=世卫组织：艾滋病毒耐药性激增，鼓励全球向度鲁特韦过渡, objectType=article, longId=176684, objectId=b6181e6684b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6181e6684b5, replyNumber=0, likeNumber=85, createdTime=2020-02-24, rootId=0, userName=zhyy96, userId=42c123781077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6181e6684b5, moduleTitle=世卫组织：艾滋病毒耐药性激增，鼓励全球向度鲁特韦过渡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6181e6684b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649231, encodeId=fe7d164923161, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, objectTitle=Lancet：度鲁特韦联合拉米夫定可作为HIV感染者的首先治疗方案, objectType=article, longId=153251, objectId=cb4915325177, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb4915325177, replyNumber=0, likeNumber=92, createdTime=2019-01-17, rootId=0, userName=zhyy96, userId=42c123781077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb4915325177, moduleTitle=Lancet：度鲁特韦联合拉米夫定可作为HIV感染者的首先治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb4915325177)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649228, encodeId=c96f1649228cf, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, objectTitle=Lancet Oncol：度鲁特韦或可降低抗艾滋治疗中产生的对非腺苷逆转录酶抑制剂的耐药性。, objectType=article, longId=121238, objectId=17aa1212380f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17aa1212380f, replyNumber=0, likeNumber=87, createdTime=2018-04-06, rootId=0, userName=zhyy96, userId=42c123781077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17aa1212380f, moduleTitle=Lancet Oncol：度鲁特韦或可降低抗艾滋治疗中产生的对非腺苷逆转录酶抑制剂的耐药性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17aa1212380f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649229, encodeId=cd49164922927, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, objectTitle=Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究, objectType=article, longId=125930, objectId=85ca1259307a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ca1259307a, replyNumber=0, likeNumber=82, createdTime=2018-09-30, rootId=0, userName=zhyy96, userId=42c123781077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ca1259307a, moduleTitle=Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85ca1259307a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649230, encodeId=8a1716492303a, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, objectTitle=Lancet HIV：度鲁特韦强化治疗可进一步清楚患者体内残余病毒, objectType=article, longId=134632, objectId=9ab913463247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ab913463247, replyNumber=0, likeNumber=82, createdTime=2019-03-07, rootId=0, userName=zhyy96, userId=42c123781077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ab913463247, moduleTitle=Lancet HIV：度鲁特韦强化治疗可进一步清楚患者体内残余病毒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ab913463247)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

度鲁特韦

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#泰诺福韦# #HTLV-1# #Mcl-1# #度鲁特韦#

2025-07-28发表于上海

zhyy96 (审核中...)

前往app查看评论内容

#度鲁特韦#

N Engl J Med：度鲁特韦（Dolutegravir）作为儿童HIV-1感染的一线或二线治疗优于标准治疗

2022-05-04

zhyy96 (审核中...)

前往app查看评论内容

#度鲁特韦#

NEJM：HIV感染二线治疗选择——度鲁特韦方案vs达芦那韦方案

2021-11-20

zhyy96 (审核中...)

前往app查看评论内容

#度鲁特韦#

Lancet HIV：度鲁特韦作为一线ART方案效果模型研究

2020-11-06

zhyy96 (审核中...)

前往app查看评论内容

#度鲁特韦#

NEJM：度鲁特韦联合富马酸替诺福韦治疗HIV

2019-09-18

zhyy96 (审核中...)

前往app查看评论内容

#度鲁特韦#

真实世界研究显示，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法是HIV-1患者安全且有效的疗法

2019-05-22

zhyy96 (审核中...)

前往app查看评论内容

#度鲁特韦#

世卫组织：艾滋病毒耐药性激增，鼓励全球向度鲁特韦过渡

2020-02-24

zhyy96 (审核中...)

前往app查看评论内容

#度鲁特韦#

Lancet：度鲁特韦联合拉米夫定可作为HIV感染者的首先治疗方案

2019-01-17

zhyy96 (审核中...)

前往app查看评论内容

#度鲁特韦#

Lancet Oncol：度鲁特韦或可降低抗艾滋治疗中产生的对非腺苷逆转录酶抑制剂的耐药性。

2018-04-06

zhyy96 (审核中...)

前往app查看评论内容

#度鲁特韦#

Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究

2018-09-30

zhyy96 (审核中...)

前往app查看评论内容

#度鲁特韦#

Lancet HIV：度鲁特韦强化治疗可进一步清楚患者体内残余病毒

2019-03-07

科室
- - 订阅+
  - 更多科室
工具
服务